May 21, 2021
A new study published in The Lancet shows the results of Phase 2a and Phase 3 clinical trials for the effectiveness of mTOR inhibition to bolster the aging immune system against respiratory illnesses. Immunosenescence increases disease risk As we grow older, our immune systems become increasingly dysfunctional and less able to defend us from the...
April 10, 2017
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis. PureTech have recently announced a joint venture with Novartis called resTORbio and are...